A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-30

Study Completion Date

2018-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

NCT03372044

Healthy

COMPLETED PHASE1

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS

NCT03871439

Healthy

COMPLETED PHASE1

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

NCT03092232

Healthy

COMPLETED PHASE1

A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults

NCT06393517

Healthy Participants

COMPLETED PHASE1

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

NCT05431153

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-06882961

Group Type EXPERIMENTAL

PF-06882961 Immediate Release Tablet

Intervention Type DRUG

Immediate Release Tablet

PF-06882961 Controlled Release Tablet (long)

Intervention Type DRUG

Controlled Release tablet (long)

PF-06882961 Controlled Release Tablet (short)

Intervention Type DRUG

Controlled Release tablet (short)

PF-06882961 Immediate Release Solution

Intervention Type DRUG

PF-06882961 Immediate Release solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06882961 Immediate Release Tablet

Immediate Release Tablet

Intervention Type DRUG

PF-06882961 Controlled Release Tablet (long)

Controlled Release tablet (long)

Intervention Type DRUG

PF-06882961 Controlled Release Tablet (short)

Controlled Release tablet (short)

Intervention Type DRUG

PF-06882961 Immediate Release Solution

PF-06882961 Immediate Release solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy female subjects of nonchildbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive
* Body mass index (BMI) within 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb)
* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study

Exclusion Criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis), cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* A positive urine drug test.
* History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects within 6 months before screening.
* Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
* Subjects who have previously participated in prior studies with PF 06882961 as the investigational product.
* Screening supine BP\>=140 mm Hg (systolic) or \>=90 mm Hg (diastolic), following at least 5 minutes of supine rest.
* Screening supine 12 lead ECG demonstrating a QTc interval \>450 msec or a QRS interval \>120 msec.
* Aspartate aminotransferase (AST) level \>= 1.25 × upper limit of normal (ULN);
* Alanine aminotransferase (ALT) level \>= 1.25 × ULN;
* Total bilirubin level \>=1.5 × ULN;
* TSH \> ULN;
* HbA1c \>=6.5%.
* Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for at least 28 days after the last dose of investigational product.
* Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product
* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
* History of sensitivity to heparin or heparin induced thrombocytopenia.
* History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or subjects with suspected MTC per the investigator's judgement.
* Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of the protocol.
* Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes